These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23175700)

  • 1. Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice.
    Baccala R; Gonzalez-Quintial R; Schreiber RD; Lawson BR; Kono DH; Theofilopoulos AN
    J Immunol; 2012 Dec; 189(12):5976-84. PubMed ID: 23175700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.
    Schwarting A; Paul K; Tschirner S; Menke J; Hansen T; Brenner W; Kelley VR; Relle M; Galle PR
    J Am Soc Nephrol; 2005 Nov; 16(11):3264-72. PubMed ID: 16221871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
    Moser K; Kalies K; Szyska M; Humrich JY; Amann K; Manz RA
    Arthritis Rheum; 2012 Apr; 64(4):1237-46. PubMed ID: 22006377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice.
    Schwarting A; Wada T; Kinoshita K; Tesch G; Kelley VR
    J Immunol; 1998 Jul; 161(1):494-503. PubMed ID: 9647261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
    Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
    Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.
    Kikawada E; Lenda DM; Kelley VR
    J Immunol; 2003 Apr; 170(7):3915-25. PubMed ID: 12646661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I IFN protects against murine lupus.
    Hron JD; Peng SL
    J Immunol; 2004 Aug; 173(3):2134-42. PubMed ID: 15265950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with a laminin-derived peptide suppresses lupus nephritis.
    Amital H; Heilweil M; Ulmansky R; Szafer F; Bar-Tana R; Morel L; Foster MH; Mostoslavsky G; Eilat D; Pizov G; Naparstek Y
    J Immunol; 2005 Oct; 175(8):5516-23. PubMed ID: 16210660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
    Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI.
    Liu W; Szalai A; Zhao L; Liu D; Martin F; Kimberly RP; Zhou T; Carter RH
    Arthritis Rheum; 2004 Jun; 50(6):1884-96. PubMed ID: 15188365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus.
    Satoh M; Weintraub JP; Yoshida H; Shaheen VM; Richards HB; Shaw M; Reeves WH
    J Immunol; 2000 Jul; 165(2):1036-43. PubMed ID: 10878381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of basement membrane-reactive B cells in BXSB, (NZBxNZW)F1, NZB, and MRL/lpr lupus mice.
    Clark AG; Fan Q; Brady GF; Mackin KM; Coffman ED; Weston ML; Foster MH
    Autoimmunity; 2013 May; 46(3):188-204. PubMed ID: 23157336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
    J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD47 deficiency ameliorates autoimmune nephritis in Fas(lpr) mice by suppressing IgG autoantibody production.
    Shi L; Bian Z; Chen CX; Guo YN; Lv Z; Zeng C; Liu Z; Zen K; Liu Y
    J Pathol; 2015 Nov; 237(3):285-95. PubMed ID: 26095930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Th17-Associated Interstitial Kidney Inflammation in Lupus-Prone Mice Lacking the Gene Encoding STAT-1.
    Yiu G; Rasmussen TK; Ajami B; Haddon DJ; Chu AD; Tangsombatvisit S; Haynes WA; Diep V; Steinman L; Faix J; Utz PJ
    Arthritis Rheumatol; 2016 May; 68(5):1233-44. PubMed ID: 26636548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon.
    Jacob CO; van der Meide PH; McDevitt HO
    J Exp Med; 1987 Sep; 166(3):798-803. PubMed ID: 3114409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terminal deoxynucleotidyl transferase deficiency decreases autoimmune disease in MRL-Fas(lpr) mice.
    Feeney AJ; Lawson BR; Kono DH; Theofilopoulos AN
    J Immunol; 2001 Sep; 167(6):3486-93. PubMed ID: 11544342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice.
    Liu Z; Bethunaickan R; Huang W; Ramanujam M; Madaio MP; Davidson A
    J Immunol; 2011 Aug; 187(3):1506-13. PubMed ID: 21705616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic complementation results in augmented autoantibody responses to lupus-associated antigens.
    Sim DL; Bagavant H; Scindia YM; Ge Y; Gaskin F; Fu SM; Deshmukh US
    J Immunol; 2009 Sep; 183(5):3505-11. PubMed ID: 19667095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis.
    Ozmen L; Roman D; Fountoulakis M; Schmid G; Ryffel B; Garotta G
    Eur J Immunol; 1995 Jan; 25(1):6-12. PubMed ID: 7843255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.